Clinical Trial Update: Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating PET imaging tracers Fluorine F18-EF5 and Fludeoxyglucose F18 to assess hypoxia and glycolysis in stage I-III non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fludeoxyglucose F18 (Fludeoxyglucose F18)
• Fluorine F18-EF5 (Fluorine-18 EF5 tracer)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED